Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CANbridge Pharmaceuticals Inc.
北 海 康 成 製 藥 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

(1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS; AND (2) CHANGE IN COMPOSITION OF BOARD COMMITTEES

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (each, a "**Director**" and collectively, the "**Directors**") of CANbridge Pharmaceuticals Inc. (the "**Company**") hereby announces that, with effect from August 5, 2026, Dr. Richard James Gregory ("**Dr. Gregory**") has resigned as an independent non-executive Director, the chairman of the remuneration committee of the Company (the "**Remuneration Committee**") and a member of the audit committee of the Company (the "**Audit Committee**") due to changes in his personal arrangements.

Dr. Gregory has confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**") and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board would like to take this opportunity to express its sincere gratitude to Dr. Gregory for his valuable contributions to the Company during his tenure of office.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board hereby announces that Dr. Richard Arthur Moscicki ("**Dr. Moscicki**") has been appointed as an independent non-executive Director, the chairman of the Remuneration Committee and a member of the Audit Committee with effect from August 5, 2026 (the "**Effective Date**").

Dr. Moscicki, aged 74, received his doctor of medicine degree from Northwestern University Medical School (Honor Program in Medical Education) in 1976 and a bachelor of science degree from Northwestern University in 1974. Dr. Moscicki has served as a director of the Reagan-Udall Foundation for the Food and Drug Administration ("**FDA**") since 2023. He has also served as the chairman of the board of the Clinical Trials Access Collaborative since 2023. Since July 2022, he has served as a member of the executive committee of equitable breakthroughs in medicine development at Yale University. Dr. Moscicki has served as a director of KSQ Therapeutics, Inc. since September 2018.

From December 2018 to November 2022, he served as the chairman of the board of LogicBio Therapeutics, Inc. (formerly listed on NASDAQ, stock code: LOGC). From October 2017 to summer of 2022, he served as the executive vice president of the science and regulatory advocacy and chief medical officer of Pharmaceutical Research and Manufacturers of America. From June 2018 to October 2020, he served as a director of Akcea Therapeutics, Inc. (formerly listed on NASDAQ, stock code: AKCA). From 2013 to 2017, he served as the deputy center director for science operations at the Center for Drug Evaluation and Research of the FDA. From 1992 to 2013, he served consecutively as director, acting senior vice president and biotherapeutics vice president of medical affairs, vice president (corporate officer) of clinical development & medical affairs, senior vice president of biomedical and regulatory affairs, chief medical officer, senior vice president of clinical development & medical affairs, and senior vice president and head of clinical development at Genzyme Corporation (formerly listed on NASDAQ, stock code: GENZ). From 1983 to 2013, he has served as attending physician and assistant director of clinical outpatient sessions of allergy associates and inpatient consultations in allergy/immunology at Massachusetts General Hospital.

The Company has entered into a service agreement with Dr. Moscicki in relation to his appointment as an independent non-executive Director, with effect from the Effective Date. Dr. Moscicki will hold office from the Effective Date until the next annual general meeting of the Company, at which he will be eligible for re-election in accordance with and subject to the Memorandum and the Articles of Association of the Company (the "**Articles of Association**"). Upon being re-elected thereof, his appointment shall continue for a period of three years and until the conclusion of the annual general meeting of the Company after the re-election, or such earlier date pursuant to the Articles of Association. Dr. Moscicki will receive an annual Director's fee of US$45,000, which is determined with reference to his duties and responsibilities with the Company, the Company's performance and market situation.

Save as disclosed above, Dr. Moscicki confirmed that, (i) he does not hold, and has not held in the last three years, any other directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (ii) he does not hold any other major appointment or professional qualification; (iii) he has no relationship with any Directors, senior management or substantial shareholders (as defined in the Listing Rules) of the Company, nor does he hold any other positions with the Company or any of its subsidiaries; and (iv) he is not interested or deemed to be interested in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Dr. Moscicki confirmed that (i) he has satisfied all the criteria for independence set out in Rule 3.13(1) to (8) of the Listing Rules; (ii) he had no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected persons of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, there is no other information in relation to the appointment of Dr. Moscicki that needs to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, and there are no other matters concerning the appointment of Dr. Moscicki that should be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board takes this opportunity to welcome Dr. Moscicki on his new appointments.

By Order of the Board
CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司
Dr. James Qun Xue
Chairman

Hong Kong, August 5, 2026

As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director; Ms. Wei Zhao and Mr. Tingwei Wang as non-executive Directors; and Dr. Richard Arthur Moscicki, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.